Physician profile
Derek J Brown
NPI 1659597524
$1,343.74
in general payments reported to CMS, 2019-2025
24 companies · $212 in 2025
The $212 reported for 2025 was more than what 75% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $38.13 · 2021: $104 · 2022: $353 · 2023: $210 · 2024: $264 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.27 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $162.67 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $153.07 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $141.22 | 2019-2024 | Capvaxive, Gardasil 9, Vaxneuvance |
| Glaxosmithkline, LLC. | $128.23 | 2019 | |
| Seqirus USA INC | $102.75 | 2022-2023 | Flucelvax Quadrivalent |
| Insulet Corporation | $73.33 | 2024 | Omnipod |
| Lilly USA, LLC | $64.02 | 2022-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.09 | 2021-2024 | Xifaxan |
| Pfizer INC. | $53.83 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.58 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $51.34 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $42.57 | 2022 | |
| Phathom Pharmaceuticals, INC. | $39.07 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.63 | 2021-2023 | Jardiance |
| Dexcom, INC. | $27.38 | 2024 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26.31 | 2019-2024 | Farxiga |
| Abbvie INC. | $21.38 | 2022 | |
| Viatris Specialty LLC | $20.05 | 2025 | Yupelri |
| Smith+Nephew, INC. | $18.53 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.04 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.63 | 2025 | Caplyta |
| Boston Scientific Corporation | $13.42 | 2022 | |
| Agios Pharmaceuticals, INC. | $13.23 | 2023 | Pyrukynd |
| Sanofi Pasteur INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.